Literature DB >> 25940143

[Gastroparesis. Definition, diagnostics, and therapy].

U von Arnim1.   

Abstract

Gastroparesis is characterized by a constellation of upper gastrointestinal symptoms in association with delayed gastric emptying in the absence of mechanical outlet obstruction from the stomach. Major symptoms are nausea, vomiting, early satiety or postprandial fullness, bloating, and abdominal or epigastric pain. Idiopathic, diabetic, and postsurgical causes represent the most common etiologies. Diagnostic procedures for the evaluation of gastroparesis comprise gastric emptying scintigraphy (gold standard), (13)C-octanoate breath testing, and a wireless motility capsule. Management of gastroparesis includes normalization of nutritional state, relief of symptoms, glycemic control, and improvement of gastric emptying. Medical treatment entails use of prokinetic drugs, which are currently the first-line therapy. Nausea and vomiting might be positively influenced by antiemetic drugs. Gastric electronic stimulation and surgical interventions should be used in well-defined patients and represent a therapeutic option in tertiary centers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25940143     DOI: 10.1007/s00108-014-3604-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  31 in total

1.  Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis.

Authors:  Ling Wang
Journal:  J Tradit Chin Med       Date:  2004-09       Impact factor: 0.848

Review 2.  Clinical practice. Diabetic gastroparesis.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

3.  Tricyclic antidepressants for chronic vomiting in diabetic patients.

Authors:  Mandeep S Sawhney; Chandra Prakash; Patrick J Lustman; Ray E Clouse
Journal:  Dig Dis Sci       Date:  2006-12-30       Impact factor: 3.199

4.  Assessment of gastric emptying using a low fat meal: establishment of international control values.

Authors:  G Tougas; E Y Eaker; T L Abell; H Abrahamsson; M Boivin; J Chen; M P Hocking; E M Quigley; K L Koch; A Z Tokayer; V Stanghellini; Y Chen; J D Huizinga; J Rydén; I Bourgeois; R W McCallum
Journal:  Am J Gastroenterol       Date:  2000-06       Impact factor: 10.864

5.  Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity.

Authors:  Henry P Parkman; Katherine Yates; William L Hasler; Linda Nguyen; Pankaj J Pasricha; William J Snape; Gianrico Farrugia; Kenneth L Koch; Thomas L Abell; Richard W McCallum; Linda Lee; Aynur Unalp-Arida; James Tonascia; Frank Hamilton
Journal:  Gastroenterology       Date:  2010-10-20       Impact factor: 22.682

6.  A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers.

Authors:  R S Choung; N J Talley; J Peterson; M Camilleri; D Burton; W S Harmsen; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2007-03       Impact factor: 3.598

7.  Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders.

Authors:  B Drolet; G Rousseau; P Daleau; R Cardinal; J Turgeon
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

8.  Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index.

Authors:  D A Revicki; A M Rentz; D Dubois; P Kahrilas; V Stanghellini; N J Talley; J Tack
Journal:  Aliment Pharmacol Ther       Date:  2003-07-01       Impact factor: 8.171

9.  Effect of endoscopic sclerotherapy of esophageal varices on vagus nerve integrity.

Authors:  A A Masclee; C B Lamers
Journal:  J Hepatol       Date:  1994-11       Impact factor: 25.083

10.  A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis.

Authors:  R W McCallum; D A Ricci; H Rakatansky; J Behar; J B Rhodes; G Salen; J Deren; A Ippoliti; H W Olsen; K Falchuk
Journal:  Diabetes Care       Date:  1983 Sep-Oct       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.